Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
chemotherapy
Research
Homing in on one HDAC sees early success in a lung cancer
Though there are four FDA-approved HDAC inhibitors to treat some lymphomas, there’s less evidence for their efficacy in solid tumors.
Helen Floersh
Mar 20, 2023 11:54am
Merck's Keytruda combo tacks on another loss for TIGIT class
Mar 16, 2023 4:05pm
G1 sheds staff while Sorrento WARNs of layoffs
Mar 1, 2023 2:02pm
Dual drug nanoparticle could curb chemo resistance
Nov 29, 2022 9:50am
New treatment shows early potential for childhood brain cancer
Nov 15, 2022 3:45pm
What tells our gut to vomit? Scientists have new clues
Nov 2, 2022 3:35am